fc 1

3-CPMT (FC-1) is a dopamine uptake inhibitor and a potent long-acting antihistaminic agent.

FC 11 is a highly potent focal adhesion Ki nase (FAK) PROTAC®Degrader (DC50 values are 40 to 370 pM depending on cell line), which is composed of the FAK inhibitor PF 562217 joined by a linker to the cereblon-binding ligand Pomalidomide. The effects of FC 11 are reversible upon compound wash out. FC 11 also degrades autophosphorylated FAK (pFAKtyr397), displaying near complete degradation after 3 hours at 100 nM in TM3 cells.

Fc 11a-2, a benzimidazole compound, functions as an orally active, potent inhibitor of the NLRP3 inflammasome by blocking caspase-1 activation and thus preventing the activation of IL-1β/IL-18. Additionally, Fc 11a-2 inhibits the progression of Dextran sulfate sodium (DSS)-induced murine experimental colitis [1] [2] [3].

Etanercept is a fusion protein consisting of the soluble portion of the p75-tumor necrosis factor receptor (TNFR) and the Fc fragment of human IgG1 and is commonly used to treat patients with rheumatoid arthritis.[1]

1. Notoginsenoside Fc has perfect anti-platelet aggregatory effect.

hIgG-hFc receptor-IN-1 is a human immunoglobulin G - human neonatal Fc receptor (hIgG-hFcRn) protein-protein interaction inhibitor (IC50: 2 μM).

Cadonilimab (AK104) is a tetravalent PD-1/CTLA-4 bispecific humanised antibody that activates T cells by enhancing IL-2 and IFN-γ secretion while reducing pro-inflammatory cytokine secretion (e.g., IL-6, IL-8). It offers low toxicity and high affinity, making it suitable for metastatic cervical, gastric, hepatic, and pulmonary cancers, pancreatic cancer, and oesophageal squamous cell carcinoma.

Ocaratuzumab (AME 133v), an Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody, demonstrates enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) [1] [2] with a dissociation constant (Kd) of approximately 100 pM.

Visilizumab is a humanized IgG2 monoclonal antibody engineered to target the CD3 antigen on T-cells while exhibiting low Fc receptor binding activity to minimize activation-induced cytotoxicity. this unique design potentially suppresses the body's immune response through the modulation of T-cell function, and Visilizumab can be used in studies about the treatment of ulcerative colitis and Crohn's disease.

Anbenitamab (KN-026) is a bispecific antibody targeting extracellular domains II and IV of human HER2, blocking both ligand-dependent and independent signaling pathways. Its IgG1 Fc fragment activates FcRγIIIa, triggering strong antibody-dependent cell-mediated cytotoxicity (ADCC) and suppressing tumor cell growth. Anbenitamab shows promise for research in HER2-positive metastatic breast cancer (MBC) [1][2].

Asunercept (APG101; CAN008), a soluble CD95-Fc fusion protein, selectively targets and binds to CD95L, effectively disrupting CD95/CD95L signaling. It is utilized in research for treating glioblastoma multiforme (GBM), myelodysplastic syndrome (MDS), and graft-versus-host disease (GvHD) [1] [2] [3].

Tecaginlimab (BNT-312), an Fc-inert bispecific antibody, is designed for the dual targeting and conditional activation of CD40 and 4-1BB, aiming to improve the priming and reactivation of tumor-specific immunity [1].

Inbakicept is a dimer of IL-15 receptor alpha sushi domain and immunoglobulin G1 (human Fc fragment) fusion protein, which is an IL-15 super agonist protein complex. Inbakicept binds to IL-15 antibody Nogapendekin alfa to form the complex Nogapendekin alfa inbakicept (ALT-803) in a 1:2 ratio. ALT-803 has potential anticancer and anti-tumor activities, which can be used to study breast cancer.

Lenercept (Ro 45-2081) is a recombinant fusion protein that combines the soluble TNF-receptor (p55) with the Fc portion of human IgG1 [1].

Letolizumab (BMS-986004) is a dimeric antibody targeting CD40L for the expression of mutant IgG1 that lacks effector functions including Fc binding and complement binding.1 Letolizumab does not induce platelet activation in vitro and does not affect coagulation factors or platelet counts/function after repeated dosing in non-human primates.

Pavurutamab (AMG-701) is a bispecific T-cell engager targeting CD3 and B-cell maturation antigens (BCMA), with an extended half-life derived from Pacanalotamab. Its Fc region is engineered for improved pharmacokinetics, offering potential in immune regulation and treatment of multiple myeloma (MM) [1] [2] [3] [4].

Cosibelimab (CK-301; TG-1501) is a fully human, high-affinity monoclonal antibody that inhibits PD-L1 by preventing its interaction with PD-1. Featuring a functional Fc domain, this compound effectively induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), targeting and eliminating PD-L1+ cell lines, including lymphoma cells [1].

Eflepedocokin alfa is a recombinant fusion protein comprising human IL-22 fused with the human IgG2-Fc domain, exhibiting cell protective activity. It activates the IL-22/IL-22R-mediated signal transduction pathways, including STAT3, playing a critical role in immune response to bacterial infections. It enhances intestinal barrier function, boosts intestinal immunity, and facilitates tissue repair [1].

Efruxifermin, an Fc-FGF21 fusion protein consisting of a human IgG1 Fc domain linked to modified human FGF21, exhibits a prolonged half-life and enhanced receptor affinity compared to its native counterpart. It is utilized in researching non-alcoholic steatohepatitis [1].

Rimteravimab (XVR011) is a bivalent VHH-Fc antibody that targets the disease caused by SARS-CoV-2, exhibiting potent neutralizing activity, high stability, broad coverage, and silenced Fc effector functions [1].

Briobacept (BR 3FC), a selective human monoclonal antibody, targets BLyS (BAFF) to induce B-cell apoptosis and is a recombinant glycoprotein comprising two BLyS receptor (BR3) molecules fused to the Fc domain of human IgG1. It has applications in the study of rheumatoid arthritis (RA) [1] [2].

Human IgG2 kappa, Isotype Control is a chimeric monoclonal antibody recombinantly expressed from HEK293 cells, which is engineered by combining the antigen-binding variable region derived from a mouse monoclonal antibody with the constant domain of a human IgG2 kappa immunoglobulin, thus serving as an immunological control for non-specific binding and Fc receptor interactions.

Batoclimab (RVT-1401) is a fully humanized immunoglobulin G1 (IgG1) monoclonal antibody that specifically targets the neonatal Fc receptor (FcRn) with high affinity for the IgG-binding site on FcRn, and by competitively binding to this site, Batoclimab effectively blocks FcRn-mediated recycling of immunoglobulin G (IgG), resulting in the enhanced degradation of IgG and subsequent reductions in circulating IgG levels, making it a candidate compound for research in autoimmune diseases such as myasthenia gravis and thyroid eye disease.

Telitacicept (RC18), a fully human TACI-Fc fusion protein, acts as a dual inhibitor of B lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand), effectively impeding B lymphocyte proliferation. This compound is applicable in researching B-cell autoimmune diseases [1].